Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study.
Adriana Zanoni DottiDaniela Oliveira MagroEduardo Garcia VilelaJúlio Maria Fonseca ChebliLiliana Andrade ChebliFlavio SteinwurzMarjorie Costa ArgolloNayara Salgado CarvalhoJose Miguel Luz ParenteMurilo Moura LimaRogério Serafim ParraRamir Luan PerinCristina FloresEloá Marussi MorsolettoSandro da Costa FerreiraJuliano Coelho LudvigRoberto Luiz Kaiser JuniorMikaell Alexandre Gouvea FariaGuilherme Mattioli NicollelliAdriana Ribas AndradeNatália Souza Freitas QueirozPaulo Gustavo KotzePublished in: Crohn's & colitis 360 (2023)
This study demonstrates the effectiveness and safety of vedolizumab as a first-line biological agent in patients with mild-to-moderate CD.